Morrisville, NC – According to filings with the U.S. Securities and Exchange Commission, Locus Biosciences is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Paul Garofolo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Locus Biosciences

We are an emerging biotechnology company that develops precision antibacterial products. We have assembled an experienced team of leaders in CRISPR and antibacterial drug development to drive our products into clinical development. Our CRISPR-Cas3 enhanced bacteriophage products kill target bacteria by irreversibly destroying their DNA, while leaving the many species of good bacteria in the body unharmed.

To learn more about Locus Biosciences, visit http://www.locus-bio.com/

Contact:
Paul Garofolo, Chief Executive Officer
919-313-9648
paul.garofolo@locus-bio.com
https://www.linkedin.com/in/paulgarofolo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved